CONMED Corporation 2013 First-Quarter Form 10-Q Summary
Business Context and Reporting Period
CONMED is a global medical technology company that develops, manufactures and sells surgical devices and equipment for minimally invasive procedures and monitoring. Products serve orthopedic, general surgery, gynecology, neurosurgery and gastroenterology markets. Effective January 1, 2013, the Company began reporting as a single operating segment. This unaudited filing covers the three months ended March 31, 2013, compared with the same period in 2012.
International sales represented approximately 50.5% of first-quarter 2013 net sales. Product-line sales were orthopedic surgery, $105.0 million; general surgery, $66.8 million; and surgical visualization, $15.2 million.
Key Financial Metrics
| Metric | Q1 2013 | Q1 2012 | Change |
|---|---|---|---|
| Net sales | $187.0 million | $194.3 million | Down 3.8% |
| Gross profit | $102.7 million | $100.9 million | Up 1.8% |
| Gross margin | 54.9% | 51.9% | Up 3.0 percentage points |
| Income from operations | $15.9 million | $17.0 million | Down 6.8% |
| Operating margin | 8.5% | 8.7% | Down 0.2 percentage points |
| Net income | $10.5 million | $10.0 million | Up 5.3% |
| Diluted EPS | $0.37 | $0.35 | Up $0.02 |
| Net cash from operating activities | $5.5 million | $7.6 million | Down $2.2 million |
Selling and administrative expense increased to $77.7 million from $74.8 million, while research and development expense declined to $5.7 million from $7.1 million. The 2013 results included $1.6 million of medical device excise tax expense. The effective tax rate declined to 26.3% from 36.0%, primarily due to foreign earnings at lower tax rates and tax benefits, including a $0.8 million research and development credit.
Cash and cash equivalents were $32.4 million at March 31, 2013, compared with $23.7 million at December 31, 2012. Net working capital was $256.8 million. Capital expenditures were $4.1 million during the quarter, and management expected approximately $20.0 million of capital expenditures for full-year 2013.
Debt and Liquidity
- CONMED entered into a $350.0 million amended and restated revolving credit facility expiring January 17, 2018. Initial pricing was LIBOR plus 1.50%; the rate was 1.71% at March 31, 2013.
- Borrowings under the revolving facility were $217.0 million, with $123.2 million of available capacity and approximately $9.8 million reserved for letters of credit.
- Total long-term debt included $8.6 million outstanding under a mortgage note and approximately $0.2 million of convertible senior subordinated notes due 2024.
- The Company recorded a $0.3 million loss on early extinguishment of debt related to refinancing.
- Management stated that operating cash flow, cash on hand and available borrowing capacity should be adequate for anticipated working capital, debt service, capital expenditures and share repurchases. The Company was in compliance with credit agreement covenants at March 31, 2013.
Material Changes Versus the Prior Comparable Period
- Sales declined across all product lines. Orthopedic surgery decreased 1.7%, general surgery decreased 3.9%, and surgical visualization decreased 15.6%.
- Management attributed the sales decline partly to fewer selling days, including the timing of Easter and Passover and the absence of 2012 leap-year timing. Capital equipment sales also reflected hospital capital-purchasing constraints.
- Gross margin improved from 51.9% to 54.9%, primarily due to savings from completed operational restructuring.
- Operating income declined despite higher gross profit because selling and administrative expense, incentive compensation, medical device excise tax and restructuring costs increased.
- Net income and diluted EPS increased primarily because of the lower effective tax rate.
- Operating cash flow declined due largely to higher pension contributions and payments related to the medical device excise tax.
- The Company paid $34.0 million of contingent consideration under its MTF sports medicine joint development and distribution agreement. A further $50.0 million was accrued because management believed the related supply targets were probable to be met; $16.7 million was due within the next fiscal year.
- The Company repurchased $25.7 million of common stock, or 848,386 shares, during the quarter. The $200.0 million authorization had $79.1 million remaining at March 31, 2013.
Guidance, Outlook, Risks and Unusual Items
- Management was cautiously optimistic about domestic economic conditions but noted continuing challenges in Europe and other international markets.
- Full-year 2013 restructuring and other costs were estimated at approximately $13.0 million to $14.0 million. The Company expected the current restructuring phase and related cash payments to be substantially completed during 2013.
- Restructuring activities included manufacturing transfers to Mexico and consolidation of Finland and Westborough, Massachusetts operations. The restructuring accrual was $3.6 million at March 31, 2013.
- Key risks include hospital purchasing constraints, foreign exchange and interest-rate volatility, competition, product development and acceptance, regulatory actions, quality or product recalls, acquisition integration, material availability, patent litigation, and potential shortages of allograft tissue.
- Bonutti Skeletal Innovations filed a patent infringement lawsuit in September 2012. CONMED believes the products do not infringe and intends to defend the claims; a potential loss range could not be estimated.
- The Company maintained $25 million of product liability insurance per incident and in the annual aggregate, but warned that claims could exceed coverage or that coverage could become unavailable or more costly.
- Other unusual first-quarter 2013 items included $1.6 million of administrative consolidation costs, $1.6 million of restructuring costs in cost of sales, $0.2 million of patent-related legal costs, and the $0.3 million debt extinguishment loss.
- Forward-looking statements are subject to the risks described in the filing and the 2012 Form 10-K. The filing does not provide specific revenue or earnings guidance.
Most Important Facts for Investors to Verify
- Whether the first-quarter sales decline was primarily timing-related or reflects sustained weakness, particularly in surgical visualization and hospital capital equipment.
- Whether restructuring savings can offset higher selling expenses, incentive compensation and the medical device excise tax.
- The timing and cash funding of the remaining $50.0 million MTF contingent obligation, including the $16.7 million due within the next fiscal year.
- Revolving credit facility utilization, covenant compliance and liquidity after share repurchases, dividends and required obligations.
- The expected full-year restructuring cost range of $13.0 million to $14.0 million and whether related savings are achieved.
- The potential financial and operational impact of the Bonutti patent litigation, regulatory matters, product liability claims and allograft tissue availability.
- The sustainability of the 26.3% effective tax rate, which benefited from foreign earnings and enacted tax provisions.